Bruker Corporation (BRKR) |
|
62.3 -0.13 (-0.21%)
|
09-29 16:00 |
|
Open: |
62.97 |
Pre. Close: |
62.43 |
|
High:
|
63.41 |
Low:
|
62.07 |
|
Volume:
|
524,785 |
Market Cap:
|
9,149(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:18 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 76.93 One year: 80.56 |
| Support: |
Support1: 60.83 Support2: 50.61 |
| Resistance: |
Resistance1: 65.86 Resistance2: 68.98 |
| Pivot: |
63.49 |
| Moving Average: |
MA(5): 62.24 MA(20): 63.49 
MA(100): 69.65 MA(250): 69.76 |
| MACD: |
MACD(12,26): -1 Signal(9): -0.9 |
| Stochastic oscillator: |
%K(14,3): 18.4 %D(3): 15.7 |
| RSI: |
RSI(14): 43.4 |
| 52-week: |
High: 84.83 Low: 52.22 |
| Average Vol(K): |
3-Month: 897 (K) 10-Days: 659 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BRKR ] has closed above bottom band by 33.3%. Bollinger Bands are 4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
63.48 - 63.82 |
63.82 - 64.1 |
|
Low:
|
61.28 - 61.66 |
61.66 - 61.98 |
|
Close:
|
61.68 - 62.32 |
62.32 - 62.87 |
|
Company Description |
|
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts. |
Headline News |
Fri, 29 Sep 2023
New Mexico Educational Retirement Board Acquires 2300 Shares of ... - MarketBeat
Wed, 27 Sep 2023
Bruker Co. (NASDAQ:BRKR) Stock Position Raised by Pacer ... - MarketBeat
Thu, 21 Sep 2023
Congress Wealth Management LLC DE Purchases Shares of ... - MarketBeat
Tue, 19 Sep 2023
Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities - Nasdaq
Mon, 18 Sep 2023
State Board of Administration of Florida Retirement System Sells ... - MarketBeat
Wed, 13 Sep 2023
Should You Buy Bruker Corporation (BRKR) Stock Wednesday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
147 (M) |
| Shares Float |
99 (M) |
|
% Held by Insiders
|
32.3 (%) |
|
% Held by Institutions
|
71.8 (%) |
|
Shares Short
|
4,090 (K) |
|
Shares Short P.Month
|
4,230 (K) |
Stock Financials |
|
EPS
|
2.16 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
8.39 |
|
Profit Margin (%)
|
11.7 |
|
Operating Margin (%)
|
17.8 |
|
Return on Assets (ttm)
|
8.3 |
|
Return on Equity (ttm)
|
28.5 |
|
Qtrly Rev. Growth
|
15.8 |
|
Gross Profit (p.s.)
|
8.92 |
|
Sales Per Share
|
18.45 |
|
EBITDA (p.s.)
|
3.95 |
|
Qtrly Earnings Growth
|
17.8 |
|
Operating Cash Flow
|
342 (M) |
|
Levered Free Cash Flow
|
159 (M) |
Stock Valuations |
|
PE Ratio
|
28.84 |
|
PEG Ratio
|
1 |
|
Price to Book value
|
7.42 |
|
Price to Sales
|
3.37 |
|
Price to Cash Flow
|
26.78 |
Stock Dividends |
|
Dividend
|
0.05 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
